Source: From Ref. 23.

Source: From Ref. 23.

Sulkowski et al. (22) evaluated the effect of peg-IFN-a2a on the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy for at least three months. The subjects (n = 24) received 180 mg SC peg-IFN-a2b once weekly for four weeks and continued their methadone regimen. The results of the study indicated that treatment with peg-IFN-a2b once weekly for four weeks was associated with methadone levels that were 10% to 15% higher than that at baseline. The clinical significance of this finding is not known.

0 0

Post a comment